阿尔茨海默病和血管痴呆症,连接和区分的特征
Mikołaj Hurła1, Natalia Banaszek1, Wojciech Kozubski2
1Laboratory of Neurobiology, Department of Neurology.
Current Alzheimer research
|July 30, 2024
概括
区分阿尔茨海默氏病 (AD) 和血管痴呆症 (VD) 是一个挑战,因为重叠的症状. 研究正在探索新的生物标志物和先进的神经成像,以改善这些常见的痴呆症的诊断和治疗.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 和血管痴呆 (VD) 是导致痴呆的主要原因,临床表现重叠,但病理不同.
- 阿尔茨海默病涉及粉样斑块和神经纤维状,而静脉疾病则是脑血管损伤的结果.
- 常见的风险因素和口腔微生物群的潜在作用将这些疾病联系在一起.
研究的目的:
- 解决区分AD和VD的诊断挑战.
- 突出需要提高诊断准确度和治疗策略的需要.
- 为了探索新兴的诊断途径.
主要方法:
- 审查目前对AD和VD病理和风险因素的理解.
- 对诊断局限性的分析,包括症状重叠和当前神经影像限制.
- 探索新的生物标志物 (炎症标志物,MMP,microRNA) 和先进的神经成像技术.
主要成果:
- 显著的重叠的症状,如记忆力丧失和执行功能障碍复杂的诊断.
- 目前的生物标志物和神经成像不足以确定差异化.
- 新的生物标志物和先进的神经成像显示出区分AD和VD的希望.
结论:
- 目前需要采用综合临床,认知和成像数据的多模式诊断方法.
- 对疾病特异性生物标志物和先进的神经成像的进一步研究对于准确的诊断至关重要.
- 改进的诊断能力将使痴呆症患者的优化治疗策略成为可能.
相关概念视频
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Dementia
109
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
109
Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172


